← Back to Home

Turning “One Person, One Drug” Into a Replicable Process: Three Major Institutions Establish Center for Therapeutic Genetics

Personalized genetic medicines for rare diseases are often time-consuming and expensive to develop, with each effort starting almost from scratch. A newly established nonprofit center aims to share design, manufacturing, and clinical frameworks, beginning with inherited childhood epilepsies to test whether this model can extend beyond a small number of exceptional cases.

By SURL BioNews

For many ultra-rare genetic diseases, scientists may know the disease-causing mutation and even be able to envision how to correct it. The real difficulty, however, is producing a usable medicine for just a handful of patients. The Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory have established the Center for Therapeutic Genetics to address precisely this long and prohibitively expensive gap between genetic diagnosis and clinical treatment.

The core of this nonprofit collaboration is not to build a separate development system for every disease, but to organize reusable components into a shared platform. Drug design tools, disease models, manufacturing processes, safety data, and clinical trial protocols could all be carried over across different programs. The center also plans to share methods and data and provide training, gradually bringing personalized genetic medicines closer to a replicable clinical process.

The initial work will focus on rare inherited childhood epilepsies. A Broad-led consortium of 12 institutions has received up to $34.5 million in support from the U.S. Advanced Research Projects Agency for Health (ARPA-H) to establish the “Paediatric Epilepsy and Rare CNS Gene Editing Platform.” The initial diseases include alternating hemiplegia of childhood associated with ATP1A3 mutations and Dravet syndrome, which is often associated with SCN1A mutations.

The research team plans to combine base-editing or prime-editing technologies with an adeno-associated virus vector called TfR1 CapX. This vector is designed to cross the blood-brain barrier after intravenous infusion and deliver editing components to the central nervous system. However, the information disclosed so far still describes a research and development program, and there are not yet human efficacy or safety data sufficient to demonstrate that this delivery-and-editing combination can work in pediatric patients.

The consortium aims to advance to a first-in-human trial within three years. If shared manufacturing, regulatory, and clinical infrastructure can be reused across diseases, the next ultra-rare disease program would not need to start entirely from scratch, and development time and costs could also decline. The real test of this platform-based approach is how much can be standardized across different mutations, tissues, and dosing requirements without compromising the safety review required for each individual therapy.

The funding model is equally important to accessibility. Participants argue that therapy development should rely on philanthropic and public support rather than requiring patients’ families to raise enormous sums themselves. This addresses a longstanding dilemma for personalized medicines: while they can technically be tailored to a single patient, stable pathways for payment, manufacturing responsibility, and regulatory oversight may not exist institutionally.

The center is still in its founding stage, is not yet accepting referrals, and does not provide clinical care. In other words, this is not a new medical option that has already opened its doors to patients, but a long-term effort to reshape research and development infrastructure. Whether it can turn a small number of successful cases into a routine capability accessible to more families will depend on the results of human trials, regulatory coordination, and how much time and resources the platform actually saves across different diseases.

References

  1. The Jackson Laboratory
  2. Broad Institute
  3. The Boston Globe
  4. Broad Institute